Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96 Origin: Appendix 5. Amended 1/7/98 1/9/99 1/7/2000 30/9/2001 11/3/2002 1/1/2003

Introdu	iced 1///96. Origin: Appendix 5. Amended 1///98, 1/9/	99, 1///2000, 30/9/2001, 11/3/2002, 1/1/2003.	
Name	e of entity		
Ne	euren Pharmaceuticals Limited		
ABN			
11	1 496 130		
We (the entity) give ASX the following information.  Part 1 - All issues  You must complete the relevant sections (attach sheets if there is not enough space).			
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	Options over Ordinary Shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	3,597,122 Options (unlisted)	
3	Principal terms of the +securities (eg, if options, exercise price and	3,597,122 unlisted options with an exercise price A\$0.0334 per option and expiry date of	

expiry date; if partly paid 22 March 2014 +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

1/1/2003 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4	Do the +securities rank equally in all		
	respects from the date of allotment		
	with an existing +class of quoted		
	+securities?		

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No

On exercise of the options, the acquired Ordinary Shares will rank equally with existing Ordinary Shares

5 Issue price or consideration

Repayment of convertible note.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Repayment of convertible note.

7 Dates of entering \*securities into uncertificated holdings or despatch of certificates

22 March 2010

8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
370,079,449	Ordinary Shares

Appendix 3B Page 2 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
720,000	Ordinary Share Options exercisable at NZ\$0.392 before 31 March 2010
600,000	Ordinary Share Options exercisable at NZ\$0.472 before 31 March 2010
750,000	Ordinary Share Options exercisable at A\$0.15 before 1 October 2010
3,000,000	Ordinary Share Options exercisable at A\$0.25 before 7 February 2011
20,000,000	Ordinary Share Options exercisable at A\$0.0445 before 18 November 2013
4,629,630	Ordinary Share Options exercisable at A\$0.0389 before 4 December 2013
40,306,174	Ordinary Share Options exercisable at A\$0.0457 before 23 December 2013
14,234,876	Ordinary Share Options exercisable at A\$0.0337 before 17 February 2014
3,597,122	Ordinary Share Options exercisable at A\$0.0334 before 22 March 2014
A\$400,000	Convertible note maturing 18 November 2011

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	Not applicable
12	Is the issue renounceable or non-renounceable?	Not applicable
13	Ratio in which the *securities will be offered	Not applicable
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Not applicable
15	<sup>+</sup> Record date to determine entitlements	Not applicable

1/1/2003 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable
17	Policy for deciding entitlements in relation to fractions	Not applicable
18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	Not applicable
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	Not applicable
25	If the issue is contingent on +security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable

Appendix 3B Page 4 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

29	Date rights trading will end (if applicable)	Not applicable	
30	How do *security holders sell their entitlements in full through a broker?	Not applicable	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	Not applicable	
33	<sup>+</sup> Despatch date	Not applicable	
(a) (b)	Type of securities (tick one)  Securities described in Part 1  All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entit	ies that have ticked box 34(a	n)	
Addit	onal securities forming a new cla	ss of securities	
Tick to docume	indicate you are providing the informat nts	ion or	
35		securities, the names of the 20 largest holders of the number and percentage of additional *securities held by	
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000		

1/1/2003 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

	100,001 and over		
37	A copy of any trust deed for the additional *securities		
Entit	ies that have ticked box 34(b)	)	
38	Number of securities for which <sup>+</sup> quotation is sought	Not applicable	
39	Class of *securities for which quotation is sought	Not applicable	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Not applicable	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period	Not applicable	
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Number Not applicable	+Class

Appendix 3B Page 6 1/1/2003

<sup>+</sup> See chapter 19 for defined terms.

## **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at the 
  time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 22 March 2010

Chief Financial Officer

Print name: Mr Rob Turnbull

+ See chapter 19 for defined terms.

1/1/2003 Appendix 3B Page 7